Transcriptomic Insights into the Antitumor Mechanism of Bufalin in Hepatocellular Carcinoma Cell HepG2 DOI Creative Commons

Qinghang Song,

Huhu Zhang, Ya Li

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 30, 2023

Abstract Aim Bufalin, a cardiotonic steroid derived from Chinese toad venom, exhibits anticancer effects against variety of malignancies. However, its mechanism action in human liver cancer remains elusive. This study aimed to elucidate the molecular underpinnings bufalin's antitumor activity HepG2 hepatocellular carcinoma (HCC) cells vitro. Methods were exposed 40nM bufalin or 0nM as control, and their transcriptomes compared using RNA sequencing. Differentially expressed genes (DEGs) identified annotated, enriched pathways analyzed Gene ontology, Kyoto Encyclopedia Genes, set enrichment analysis, Genomes databases. Results sequencing revealed 771 DEGs, comprising 362 upregulated 409 downregulated genes. These DEGs involved 78 classical pathways, including 18 closely associated with cancer, such central carbon metabolism cell cycle, DNA replication, fatty acid metabolism, ferroptosis, so forth. Eleven (Acyl-CoA oxidase 2 et al.) HCC validated by quantitative real-time reverse transcription-polymerase chain reaction, confirming differential expressions response treatment. Conclusions demonstrated that modulates expression implicated various aspects pathogenesis progression, energy proliferation, lipid oxidation, death. findings suggest may exert effect on targeting multiple mechanisms, provide potential targets for bufalin-based therapy.

Language: Английский

Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy DOI
Rong Xiao, Ye Tian, Jiwei Zhang

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 80(5), P. 792 - 804

Published: Feb. 7, 2024

Language: Английский

Citations

15
A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways DOI
Md. Rezaul Islam, Abdur Rauf,

Shopnil Alash

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(6)

Published: May 4, 2024

Language: Английский

Citations

7
Bufalin-Mediated Regulation of Cell Signaling Pathways in Different Cancers: Spotlight on JAK/STAT, Wnt/β-Catenin, mTOR, TRAIL/TRAIL-R, and Non-Coding RNAs DOI Creative Commons
Ammad Ahmad Farooqi, Venera Rakhmetova, Gulnara Kapanova

et al.

Molecules, Journal Year: 2023, Volume and Issue: 28(5), P. 2231 - 2231

Published: Feb. 27, 2023

The renaissance of research into natural products has unequivocally and paradigmatically shifted our knowledge about the significant role in cancer chemoprevention. Bufalin is a pharmacologically active molecule isolated from skin toad Bufo gargarizans or melanostictus. characteristically unique properties to regulate multiple molecular targets can be used harness multi-targeted therapeutic regimes against different cancers. There burgeoning evidence related functional roles signaling cascades carcinogenesis metastasis. been reported pleiotropically myriad signal transduction various Importantly, bufalin mechanistically regulated JAK/STAT, Wnt/β-Catenin, mTOR, TRAIL/TRAIL-R, EGFR, c-MET pathways. Furthermore, bufalin-mediated modulation non-coding RNAs cancers also started gain tremendous momentum. Similarly, targeting tumor microenvironments macrophages an area exciting we have only scratch surface complicated nature oncology. Cell culture studies animal models provide proof-of-concept for impetus inhibition Bufalin-related clinical are insufficient interdisciplinary researchers require detailed analysis existing gaps.

Language: Английский

Citations

14
Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis DOI Creative Commons

Donghao Tang,

Yuejiao Feng,

Jiahao Lu

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(2), P. e24395 - e24395

Published: Jan. 1, 2024

BackgroundBufalin, the main active ingredient of traditional Chinese medicine huachansu, is used in clinical treatment colorectal cancer and has multiple effects, including inhibition migratory invasion, reversal multi-drug resistance, induction apoptosis differentiation, angiogenesis.MethodsWe collected relevant articles on bufalin from 2003 to 2022 using Web Science platform, analysed information VOSviewer, CiteSpace, Microsoft Excel categorise summarise publications over past 20 years.ResultsWe 371 papers, with a steady increase number published globally. China highest articles, whereas Japan citations. Currently, there considerable enthusiasm for investigating anti-tumour mechanism optimising drug delivery systems its administration.ConclusionFor first time, we present comprehensive overview papers worldwide two decades progress application tumour therapy. We summarised key authors, institutions, countries that have contributed field potential cancer. This will help other researchers obtain an field, enhance collaboration knowledge sharing, promote future research bufalin.

Language: Английский

Citations

4
Integrated network pharmacology, proteomics, molecular docking, and experiments in vivo and in vitro to explore the efficacy and potential mechanism of bufalin against hepatocellular carcinoma angiogenesis DOI
Yuanchao Li,

Lingwei Zhou,

Kangkang Sun

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: 345, P. 119589 - 119589

Published: March 6, 2025

Language: Английский

Citations

0
Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives DOI
Yurun Miao, Xiaojun Yang

World Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 17(4)

Published: March 24, 2025

The study conducted by Wang et al, focuses on the role of Rho GTPase activating protein 12 (ARHGAP12), in hepatocellular carcinoma (HCC). This research reveals that ARHGAP12 expression, markedly elevated malignant cells HCC, correlates strongly with adverse outcomes for patients. Furthermore, illustrates enhances ability HCC to invade and contributes their resistance tyrosine kinase inhibitors (TKIs) through modulation focal adhesion pathway. To comprehensively investigate relationship between TKI resistance, this integrates single-cell bulk RNA sequencing methodologies along data from tumor immune hub 2, Gene Expression Omnibus, Cancer Genome Atlas, CellMiner, Genomics Drug Sensitivity as well immunohistochemical staining proteomic analyses. Statistical analyses, including Wilcoxon rank-sum test receiver operating characteristic curve analysis, were employed evaluate correlation expression levels clinical parameters, drug sensitivity. It is evident a more profound exploration molecular dynamics especially those related against TKIs, essential.

Language: Английский

Citations

0
Exploration of Mechanism of Bufalin and Bufalin Derivatives in Hepatocellular Carcinoma DOI

Xinchen Gao,

Tong-hua Bian,

Xinyu Wei

et al.

Phytomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 156686 - 156686

Published: March 1, 2025

Language: Английский

Citations

0
Understanding the role of Hedgehog signaling pathway and gut dysbiosis in fueling liver cancer DOI
Naz Fatima,

Hooriya Fatima,

Sadia Ahmad

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: April 22, 2025

Language: Английский

Citations

0
Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System DOI Creative Commons
Haiqing Wang,

Wentao Bo,

Xielin Feng

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 5581 - 5603

Published: June 1, 2024

Lenvatinib (LVN) is a potentially effective multiple-targeted receptor tyrosine kinase inhibitor approved for treating hepatocellular carcinoma, metastatic renal cell carcinoma and thyroid cancer. Nonetheless, poor pharmacokinetic properties including water solubility rapid metabolic, complex tumor microenvironment, drug resistance have impeded its satisfactory therapeutic efficacy. This article comprehensively reviews the uses of nanotechnology in LVN to improve antitumor effects. With characteristic high modifiability loading capacity nano-drug delivery system, an active targeting approach, controllable release, biomimetic strategies been devised deliver target tumors sequence, compensating lack passive targeting. The existing applications advances improving efficacy include longer-term efficiency, achieving higher combination therapy, tracking diagnosing application reducing toxicity. Therefore, using multiple combined with photothermal, photodynamic, immunoregulatory therapies overcomes multi-drug resistance, regulates unfavorable yields synergistic In brief, nano-LVN system has brought light war against cancer while at same time effect. More intelligent multifunctional nanoparticles should be investigated further converted into clinical future.

Language: Английский

Citations

3
Multi-b-value DWI to evaluate the synergistic antiproliferation and anti-heterogeneity effects of bufalin plus sorafenib in an orthotopic HCC model DOI Creative Commons
Ran Guo, Fang Lü, Jiang Lin

et al.

European Radiology Experimental, Journal Year: 2024, Volume and Issue: 8(1)

Published: March 12, 2024

Abstract Background Multi- b -value diffusion-weighted imaging (DWI) with different postprocessing models allows for evaluating hepatocellular carcinoma (HCC) proliferation, spatial heterogeneity, and feasibility of treatment strategies. We assessed synergistic effects bufalin+sorafenib in orthotopic HCC-LM3 xenograft nude mice by using intravoxel incoherent motion (IVIM), diffusion kurtosis (DKI), a stretched exponential model (SEM), fractional-order calculus (FROC) model. Methods Twenty-four were divided into bufalin+sorafenib, bufalin, sorafenib groups, control group. DWI was performed 3-T scanner after 3 weeks’ to obtain true coefficient D t , pseudo-diffusion p perfusion fraction f mean diffusivity (MD), (MK), distributed (DDC), heterogeneity index α D, fractional order parameter β microstructural quantity μ . Necrotic (NF), standard deviation (SD) hematoxylin-eosin staining, microvessel density (MVD) anti-CD31 staining evaluated. Correlations parameters histopathological results analyzed, measurements compared among four groups. Results In the final 22 mice, positively correlated MVD ( r = 0.679, 0.001). Significantly good correlations MK 0.677), -0.696), -0.639) SD observed (all < 0.010). MK, MVD, much lower, while MD, NF higher bufalin plus group than 0.050). Conclusion Evaluated IVIM, DKI, SEM, FROC, found inhibit tumor proliferation angiogenesis reduce models. Relevance statement b- value provides potential metrics efficacy HCC. Key points • Bufalin combination may increase effectiveness HCC therapy. depicted angiogenesis, heterogeneity. be noninvasive method assess therapeutic efficacy. Graphical

Language: Английский

Citations

2